Off-the-Shelf CAR t cells show promise against Hard-to-Treat myeloma
NCT ID NCT04093596
First seen May 14, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This early-phase study tested a new type of cancer treatment called ALLO-715, which uses donor immune cells engineered to attack myeloma cells. It was given to 73 adults whose multiple myeloma had returned or stopped responding to at least three prior treatments. The goal was to check safety and whether adding another drug (nirogacestat) could help the cells work better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Sarah Cannon/Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
St. David's South Austin Medical Center
Austin, Texas, 78704, United States
-
Stanford Cancer Institute
Palo Alto, California, 94305, United States
-
Texas Transplant Institute
San Antonio, Texas, 78229, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.